# Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

> **NCT00651027** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- HEPATITIS C (HCV)

## Interventions

- **DRUG:** PF-868554
- **DRUG:** PF-868554
- **DRUG:** PF-868554

## Key facts

- **NCT ID:** NCT00651027
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651027, "Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00651027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*